Biocon [BIOCON] vs GlaxoSmithKline [GLAXO] Detailed Stock Comparison

Biocon Ltd.

NSE
Loading...

GlaxoSmithKline Pharmaceuticals Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Biocon Ltd. wins in 9 metrics, GlaxoSmithKline Pharmaceuticals Ltd. wins in 11 metrics, with 0 ties. GlaxoSmithKline Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Biocon Ltd. GlaxoSmithKline Pharmaceuticals Ltd. Better
P/E Ratio (TTM) 71.84 41.55 GlaxoSmithKline Pharmaceuticals Ltd.
Price-to-Book Ratio 1.68 24.80 Biocon Ltd.
Debt-to-Equity Ratio 50.02 2.09 GlaxoSmithKline Pharmaceuticals Ltd.
PEG Ratio 0.17 2.44 Biocon Ltd.
EV/EBITDA 19.22 31.46 Biocon Ltd.
Profit Margin (TTM) 3.59% 26.86% GlaxoSmithKline Pharmaceuticals Ltd.
Operating Margin (TTM) 7.63% 33.71% GlaxoSmithKline Pharmaceuticals Ltd.
EBITDA Margin (TTM) 7.63% 33.71% GlaxoSmithKline Pharmaceuticals Ltd.
Return on Equity 3.66% 47.54% GlaxoSmithKline Pharmaceuticals Ltd.
Return on Assets (TTM) 1.72% 22.58% GlaxoSmithKline Pharmaceuticals Ltd.
Free Cash Flow (TTM) $17.18B $12.65B Biocon Ltd.
Dividend Yield 0.26% 1.65% GlaxoSmithKline Pharmaceuticals Ltd.
1-Year Return 17.90% -35.63% Biocon Ltd.
Price-to-Sales Ratio (TTM) 3.37 11.14 Biocon Ltd.
Enterprise Value $643.51B $397.44B Biocon Ltd.
EV/Revenue Ratio 3.82 10.46 Biocon Ltd.
Gross Profit Margin (TTM) 67.91% 65.06% Biocon Ltd.
Revenue per Share (TTM) $133 $224 GlaxoSmithKline Pharmaceuticals Ltd.
Earnings per Share (Diluted) $4.87 $60.16 GlaxoSmithKline Pharmaceuticals Ltd.
Beta (Stock Volatility) 0.25 0.10 GlaxoSmithKline Pharmaceuticals Ltd.

Biocon Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd. Stock Performance Analysis

Loading Price Chart...

BIOCON
GLAXO

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Biocon Ltd.-0.70%1.66%-3.27%10.34%6.50%7.30%
GlaxoSmithKline Pharmaceuticals Ltd.-0.31%-3.19%-13.28%-11.99%-17.96%-13.88%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Biocon Ltd.17.90%71.09%5.03%250.57%603.49%1,357.39%
GlaxoSmithKline Pharmaceuticals Ltd.-35.63%50.14%45.44%-39.87%-9.78%324.98%

Performance & Financial Health Analysis: Biocon Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd.

MetricBIOCONGLAXO
Market Information
Market Cap i₹566.52B₹422.67B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,496,86742,008
90 Day Avg. Volume i3,790,31051,960
Last Close₹416.05₹2,115.00
52 Week Range₹331.00 - ₹440.40₹2,088.10 - ₹3,500.00
% from 52W High-5.53%-39.57%
All-Time High₹487.75 (Dec 21, 2020)₹3,872.00 (Mar 28, 2016)
% from All-Time High-14.70%-45.38%
Growth Metrics
Quarterly Revenue Growth0.09%0.10%
Quarterly Earnings Growth4.73%0.29%
Financial Health
Profit Margin (TTM) i0.04%0.27%
Operating Margin (TTM) i0.08%0.34%
Return on Equity (TTM) i0.04%0.48%
Debt to Equity (MRQ) i50.022.09
Cash & Liquidity
Book Value per Share (MRQ)₹207.92₹100.81
Cash per Share (MRQ)₹45.84₹121.65
Operating Cash Flow (TTM) i₹17.78B₹12.73B
Levered Free Cash Flow (TTM) i₹10.13B₹9.28B
Dividends
Last 12-Month Dividend Yield i0.26%1.65%
Last 12-Month Dividend i₹1.00₹54.00

Valuation & Enterprise Metrics Analysis: Biocon Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd.

MetricBIOCON (Apr 26, 2026)GLAXO (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i71.8441.55
Forward P/E i38.5636.46
PEG Ratio i0.172.44
Price to Sales (TTM) i3.3711.14
Price to Book (MRQ) i1.6824.80
Market Capitalization
Market Capitalization i₹566.52B₹422.67B
Enterprise Value i₹643.51B₹397.44B
Enterprise Value Metrics
Enterprise to Revenue i3.8210.46
Enterprise to EBITDA i19.2231.46
Risk & Other Metrics
Beta i0.250.10
Book Value per Share (MRQ) i₹207.92₹100.81

Financial Statements Comparison: Biocon Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBIOCON (2025)GLAXO (2025)
Revenue/Sales i150.52B37.26B
Cost of Goods Sold i51.98B14.73B
COGS % of Revenue i34.5%39.5%
Gross Profit i98.54B22.53B
Gross Margin i65.5%60.5%
Research & Development i6.34BN/A
Operating Income (EBIT) i16.26B11.14B
Operating Margin i10.8%29.9%
EBITDA i33.60B12.55B
EBITDA Margin i22.3%33.7%
Pre-Tax Income i18.87B12.60B
Pre-Tax Income % of Revenue i12.5%33.8%
Income Tax i4.57B3.32B
Income Tax % of Revenue i3.0%8.9%
Net Income (Profit) i14.29B9.28B
Profit Margin i9.5%24.9%

Balance Sheet & Liquidity Metrics

MetricBIOCON (2025)GLAXO (2025)
Cash & Equivalents i32.27B5.39B
Total Current Assets i162.86B34.10B
Total Current Assets % of Revenue i108.2%91.5%
Total Current Liabilities i143.34B19.05B
Total Current Liabilities % of Revenue i95.2%51.1%
Long-Term Debt i129.45B24.92M
Long-Term Debt % of Revenue i86.0%0.1%
Total Shareholders Equity i277.13B19.51B
Retained Earnings i189.59B10.59B
Retained Earnings % of Revenue i126.0%28.4%
Property, Plant & Equipment i4.32B2.70B

Cash Flow Statement Comparison

MetricBIOCON (2025)GLAXO (2025)
Operating Cash Flow i17.78B12.73B
Operating Cash Flow % of Revenue i11.8%34.2%
Capital Expenditures i-21.36B-190.05M
Free Cash Flow i17.18B12.65B
FCF Margin i11.4%34.0%
Debt Repayment i-97.70BN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBIOCONGLAXO
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i1.62B169.41M
Float Shares i583.07M41.25M
% Held by Insiders i54.07%75.65%
% Held by Institutions i24.88%7.47%
% Held by Public i21.05%16.88%

Dividend Analysis & Yield Comparison: Biocon Ltd. vs GlaxoSmithKline Pharmaceuticals Ltd.

MetricBIOCONGLAXO
Last 12-Month Dividend i₹1.00₹54.00
Last 12-Month Dividend Yield i0.26%1.65%
3-Year Avg Annual Dividend i₹1.33₹59.33
3-Year Avg Dividend Yield i0.36%1.86%
3-Year Total Dividends i₹4.00₹178.00
Ex-Dividend DateJul 04, 2025May 30, 2025